SL listing or Art. 71? Two ways into Switzerland — and when to use each

In Switzerland there are two very different ways to get a patient reimbursed, and they are not interchangeable. The regular route is inclusion on the Specialties List (SL) after a full BAG pricing-and-reimbursement assessment. The other is individual reimbursement under Art. 71a–71d KVV — a case-by-case approval, patient by patient. Choosing the wrong one can cost you Swiss volume, or cost you your global price. Here is how the decision actually works.

The trade-off in one view

Regular SL listing gives you permanent, automatic reimbursement for every eligible patient, predictable for prescribers, and scalable as a commercial channel. The cost: the ex-factory price is published on the SL — visible to every external reference-pricing system, and a data point for US net-price benchmarking. It is the right default for any product with real volume.

Art. 71a–71d does not require SL listing. The treating physician applies to the insurer for a specific patient, and the negotiated price stays confidential — it never becomes a public reference. But it carries a mandatory discount set by a pragmatic benefit assessment (benefit categories), typically 20% or more and scaled to the rating, and access is decided one patient at a time, so it is uncertain and administratively heavy. It is an exception route, not a standing channel.

So the real question is never “which is faster.” It is: does a published Swiss price help you or hurt you — and is your population small enough to run case by case?

Case 1 — list on the SL

A specialty oncology medicine, second-line, with an eligible Swiss population of roughly 1,500 patients a year and a price that is defensible against the reference countries and comparators.

Here, SL listing is clearly right. You need every eligible patient reimbursed automatically; prescribers need certainty; and the administrative load of filing an Art. 71 request for each of 1,500 patients would throttle uptake and exhaust the field. The published SL price is an acceptable cost of doing business at this volume, and CCP2 lets you add a confidential rebate on top if the net needs protecting.

Volume and permanence win — list it.

Case 2 — use Art. 71 as a strategic bypass

An ultra-rare gene therapy, one-time price around CHF 2 million, eligible Swiss population of three to six patients a year.

Now the logic inverts. First, the population is tiny, so handling access case by case is entirely feasible — a handful of applications, not 1,500. Second, and decisively: the moment a CHF 2 million price lists on the SL, it becomes a global reference point — every external reference-pricing country can see it, and it feeds US net-price modelling (unless exempted). For a product whose value is its worldwide price, publishing a Swiss number is the expensive mistake. Routing those few patients through Art. 71 keeps the price under the radar, gets patients treated, and protects your international price. The cost you accept is the mandatory benefit-tiered discount and the uncertainty of per-patient approval — a price worth paying when Swiss volume is small and global price protection is everything. Art. 71 can also serve as a bridge: access now, while you negotiate an SL agreement you can actually live with.

The ultra-rare edge case: two patients and the discount

A frequent objection from ultra-rare manufacturers: “we have two patients in Switzerland, and we refuse to pay the Art. 71 discount.” The instinct is understandable — but it usually imports large-market logic into a place it doesn’t belong.

Separate two things. First, under the revised Art. 71a–71d, the rebate is compulsory and scaled to the benefit assessment — it is not a negotiation you can simply decline and still be reimbursed through that route. Second, and more important: on two patients, that rebate is both trivial in absolute terms and confidential. It creates no published reference price. In a large market a discount is visible, precedent-setting and travels through reference pricing; a confidential rebate on two Swiss patients does none of that. So the first question is what you are actually protecting. If it is the global price, the Art. 71 rebate does not threaten it — it is invisible.

If zero discount is still the goal, there are two clean routes:

Supply the patients free of charge (compassionate use / named-patient). No reimbursement means no rebate, no price and no published reference — and the patients are still treated. For an ultra-rare where two Swiss patients are immaterial to revenue but the worldwide price is sacred, giving up a rounding-error of revenue to keep everything invisible is often the smartest play of all.
If you want revenue, minimise the rebate through the benefit rating. The compulsory discount scales inversely with assessed therapeutic benefit: the stronger the high-benefit case, the smaller the mandatory rebate. The lever is not refusing the discount — it is a well-argued benefit dossier that lands it at the bottom of the range.

What not to do is chase full, undiscounted Art. 71 reimbursement. Since the 2024 reform that route does not exist, and pursuing it only leaves the patients waiting.

The decision rule

Go SL when volume, permanence and predictable access matter, and a published Swiss price is one you can defend internationally.
Use Art. 71 when the population is small enough to manage patient by patient and a published Swiss price would do more damage abroad than the mandatory discount does at home — or as a bridge to access before an acceptable SL deal is reached.
The questionable zone is using Art. 71 as a long-term substitute for listing a high-volume product. It is not built for that: access becomes unreliable for patients, the discount compounds, and sustained use as a de facto commercial channel invites scrutiny.

The skill is not knowing the two routes exist — it is knowing which lever protects more value for your asset: Swiss revenue, or your global price. That is the call worth making before you file, not after.